---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-25-000044"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:55:10.467450+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics reports FY2024 net loss $221.3M; HARMONi enrollment complete, data mid-2025

## Summary
- Cash & short-term investments $412.3M at Dec 31, 2024, up from $186.2M at Dec 31, 2023.
- GAAP net loss $221.3M ($0.31/share) vs $614.9M ($0.99/share) prior year.
- GAAP R&D expense $150.8M vs $59.4M prior year, driven by ivonescimab development.
- HARMONi Phase III trial enrollment complete; top-line data expected mid-2025; FDA Fast Track granted.
- Pfizer collaboration to evaluate ivonescimab with vedotin ADCs in solid tumors; studies start mid-2025.

## SEC filing metadata
- accession: 0001599298-25-000044
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000044/0001599298-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000044/smmt-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-25-000044
- JSON: https://secwatch.observer/filing/0001599298-25-000044.json
- Plain text: https://secwatch.observer/filing/0001599298-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.